HK1221219A1 - -二氟苯基 -甲基- -氧吡啶- -基 甲基 咪唑烷- -二酮及含有該化合物的藥物 - Google Patents
-二氟苯基 -甲基- -氧吡啶- -基 甲基 咪唑烷- -二酮及含有該化合物的藥物Info
- Publication number
- HK1221219A1 HK1221219A1 HK16109328.6A HK16109328A HK1221219A1 HK 1221219 A1 HK1221219 A1 HK 1221219A1 HK 16109328 A HK16109328 A HK 16109328A HK 1221219 A1 HK1221219 A1 HK 1221219A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methyl
- oxopyridin
- imidazolidine
- difluorophenyl
- dione
- Prior art date
Links
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 title 2
- -1 3-methyl-2-oxopyridin-1(2h)- yl Chemical group 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Quick-Acting Or Multi-Walled Pipe Joints (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013120692 | 2013-06-07 | ||
| PCT/JP2014/065060 WO2014196623A1 (ja) | 2013-06-07 | 2014-06-06 | （＋）－５－（３，４－ジフルオロフェニル）－５－［（３－メチル－２－オキソピリジン－１（２ｈ）－イル）メチル］イミダゾリジン－２，４－ジオンおよびそれを含有する医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1221219A1 true HK1221219A1 (zh) | 2017-05-26 |
Family
ID=52008252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16109328.6A HK1221219A1 (zh) | 2013-06-07 | 2016-08-04 | -二氟苯基 -甲基- -氧吡啶- -基 甲基 咪唑烷- -二酮及含有該化合物的藥物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9518041B2 (zh) |
| EP (1) | EP3006437B1 (zh) |
| JP (1) | JP6247689B2 (zh) |
| KR (2) | KR102321814B1 (zh) |
| CN (1) | CN105531270B (zh) |
| AU (1) | AU2014275835B2 (zh) |
| BR (1) | BR112015030490B1 (zh) |
| CA (1) | CA2913858C (zh) |
| ES (1) | ES2818931T3 (zh) |
| HK (1) | HK1221219A1 (zh) |
| IL (1) | IL242861B (zh) |
| MX (1) | MX364780B (zh) |
| MY (1) | MY173075A (zh) |
| NZ (1) | NZ714700A (zh) |
| PH (1) | PH12015502661B1 (zh) |
| RU (1) | RU2668072C2 (zh) |
| SG (1) | SG11201509835RA (zh) |
| TW (1) | TWI636782B (zh) |
| WO (1) | WO2014196623A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160018517A (ko) * | 2013-06-07 | 2016-02-17 | 가껭세이야꾸가부시기가이샤 | 혈소판의 기능을 유지하기 위한 조성물 |
| CN107304205B (zh) * | 2016-04-22 | 2020-10-30 | 上海医药工业研究院 | 一种马拉韦罗中间体及其制备方法 |
| WO2018056373A1 (ja) | 2016-09-23 | 2018-03-29 | 科研製薬株式会社 | （ｒ）‐５‐（３，４‐ジフルオロフェニル）‐５‐［（３‐メチル‐２‐オキソピリジン‐１（２ｈ）‐イル）メチル］イミダゾリジン‐２，４‐ジオンの製造方法およびその製造のための中間体 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1370536A1 (en) * | 2001-03-15 | 2003-12-17 | AstraZeneca AB | Metalloproteinase inhibitors |
| JP4219270B2 (ja) | 2001-09-07 | 2009-02-04 | 科研製薬株式会社 | リバースヒドロキサム酸誘導体 |
| GB0221246D0 (en) | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
| WO2004033632A2 (en) | 2002-10-04 | 2004-04-22 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) |
| US7132432B2 (en) | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
| GB0405101D0 (en) | 2004-03-06 | 2004-04-07 | Astrazeneca Ab | Compounds |
| CA2573764A1 (en) | 2004-07-16 | 2006-02-23 | Schering Corporation | Hydantoin derivatives for the treatment of inflammatory disorders |
| US7504424B2 (en) | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| PE20071240A1 (es) | 2006-01-17 | 2008-01-14 | Schering Corp | Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios |
| WO2009154190A1 (ja) * | 2008-06-17 | 2009-12-23 | アステラス製薬株式会社 | ピリドン化合物 |
| EP2346857B1 (en) | 2008-09-24 | 2019-11-27 | Merck Sharp & Dohme Corp. | Compounds for the treatment of inflammatory disorders |
| WO2010054278A2 (en) | 2008-11-10 | 2010-05-14 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| HUE038523T2 (hu) * | 2011-12-09 | 2018-10-29 | Kaken Pharma Co Ltd | Piridon-származék és ezt tartalmazó gyógyszerkészítmény |
-
2014
- 2014-06-06 AU AU2014275835A patent/AU2014275835B2/en active Active
- 2014-06-06 CA CA2913858A patent/CA2913858C/en active Active
- 2014-06-06 RU RU2015156531A patent/RU2668072C2/ru active
- 2014-06-06 BR BR112015030490-7A patent/BR112015030490B1/pt active IP Right Grant
- 2014-06-06 CN CN201480032095.3A patent/CN105531270B/zh active Active
- 2014-06-06 US US14/895,768 patent/US9518041B2/en active Active
- 2014-06-06 EP EP14806840.6A patent/EP3006437B1/en active Active
- 2014-06-06 SG SG11201509835RA patent/SG11201509835RA/en unknown
- 2014-06-06 KR KR1020157034539A patent/KR102321814B1/ko active IP Right Grant
- 2014-06-06 WO PCT/JP2014/065060 patent/WO2014196623A1/ja active Application Filing
- 2014-06-06 NZ NZ714700A patent/NZ714700A/en unknown
- 2014-06-06 KR KR1020217035383A patent/KR102379801B1/ko active IP Right Grant
- 2014-06-06 MY MYPI2015704380A patent/MY173075A/en unknown
- 2014-06-06 ES ES14806840T patent/ES2818931T3/es active Active
- 2014-06-06 TW TW103119743A patent/TWI636782B/zh active
- 2014-06-06 JP JP2015521499A patent/JP6247689B2/ja active Active
- 2014-06-06 MX MX2015016828A patent/MX364780B/es active IP Right Grant
-
2015
- 2015-11-27 PH PH12015502661A patent/PH12015502661B1/en unknown
- 2015-11-30 IL IL242861A patent/IL242861B/en active IP Right Grant
-
2016
- 2016-08-04 HK HK16109328.6A patent/HK1221219A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181392T1 (hr) | Heterociklični spojevi i njihova uporaba | |
| HK1223351A1 (zh) | 嘧啶衍生物作為激酶抑制劑 | |
| ZA201602220B (en) | Heterocyclic compounds and uses thereof | |
| EP3046921A4 (en) | Substituted aminopyrimidine compounds and methods of use | |
| ZA201603934B (en) | Composite formulation for oral administration comprising ezetimibe and rosuvastatin | |
| ZA201508118B (en) | Herbicidally active (alkynyl-phenyl)-substituted cyclic dione compounds and derivatives thereof | |
| ZA201603272B (en) | Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin | |
| EP3020714A4 (en) | IMIDAZOLE-DICETONE COMPOUND AND USE THEREOF | |
| PL2634174T3 (pl) | Zawierająca azot pochodna heterocykliczna mająca grupę 2-iminową i zawierający ją środek do zwalczania szkodników | |
| HK1218076A1 (zh) | 穩定的培美曲塞製劑 | |
| EP2886546A4 (en) | Heterocyclic compound and use thereof | |
| EP3031449A4 (en) | Entecavir microspheres and pharmaceutical composition for parenteral administration containing same | |
| IL240875A0 (en) | Heterocyclic compounds and pharmaceutical preparations containing them | |
| HK1221219A1 (zh) | -二氟苯基 -甲基- -氧吡啶- -基 甲基 咪唑烷- -二酮及含有該化合物的藥物 | |
| EP3004085A4 (en) | IMIDAZOLE DERIVATIVES AND METHODS OF USE FOR ENHANCING THE PHARMACOKINETICS OF A MEDICAMENT | |
| EP3006420A4 (en) | CERAMIC SINTERED BODY AND ANTI-CORROSION ELEMENT, FILTER AND ANTI-HALO ELEMENT FORMED BY ITS USE | |
| EP2813508A4 (en) | HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | |
| SI2970210T1 (sl) | Pirazolilbenzo(d)imidazolni derivati | |
| EP3049341A4 (en) | Container for personal care | |
| HK1222655A1 (zh) | -{ }- -{ -嗎啉基甲基 -吡咯- -基 亞甲基}- -氧代- -二氫- -吲哚- -基 甲基 -噻唑烷- -二酮的新型鹽、其製備以及包含其的製劑 | |
| IL265481B (en) | Method for the production of (r)-5-(4,3-difluorophenyl)-5-[(3-methyl-2-oxopyridine-1(h2)-yl)methyl]imidazolidine-4,2-dione and intermediates for their production | |
| EP3013333A4 (en) | Heterocyclic compounds and methods of use thereof for the treatment of hepatitis c | |
| TH1501007248A (th) | (+)-5-(3,4ไดฟลูออโรฟีนิล)-5-[(3-เมธิล-2-ออกโซไพริดิน-1(2h)-อิล)เมธิล] อิมิดาโซลิดีน-2,4-ไดโอน และ ยาที่ประกอบด้วยสิ่งเดียวกันนั้น | |
| EP3089974A4 (en) | Novel imidazolidine-2,4-dione derivatives | |
| EP3089975A4 (en) | Novel imidazolidine-2, 4-dione derivatives |